Payment overview · 2025
General Payments
$110.80
6 reported records · 6 companies
Healthcare provider profile · identity verified
Patrick Kevin Hayden, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · RUSSELLVILLE, KY · NPI 1295847184
Verified facts
What the public records show
CMS Open Payments records show Patrick Kevin Hayden, M.D. received $110.80 in general payments during 2025 across 6 reported records.
ABBVIE INC. accounted for 19.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Paxlovid.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CREON as an associated drug or biological on 91561 records involving 20616 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Creon by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 189 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 243 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $21.20 | 19.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $20.14 | 18.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.90 | 18.0% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $18.04 | 16.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $17.18 | 15.5% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.34 | 12.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $110.80 | 6 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $20.14 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.90 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC | $18.04 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $17.18 | 1 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $14.34 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 189 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | CREON open payments reported associated product |
CMS Open Payments — General Payments 91561 supporting records · 20616 recipient NPIs · example record 1201352608 |
Creon · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
189 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
243 | 37 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 892 | 185 |
| Lisinopril | Lisinopril | 722 | 149 |
| Amlodipine Besylate | Amlodipine Besylate | 707 | 130 |
| Pantoprazole Sodium | Pantoprazole Sodium | 660 | 122 |
| Furosemide | Furosemide | 634 | 111 |
| Losartan Potassium | Losartan Potassium | 542 | 124 |
| Levothyroxine Sodium | Levothyroxine Sodium | 540 | 80 |
| Metformin Hcl | Metformin Hcl | 527 | 113 |
| Metoprolol Tartrate | Metoprolol Tartrate | 524 | 94 |
| Gabapentin | Gabapentin | 499 | 64 |
| Hydrochlorothiazide | Hydrochlorothiazide | 449 | 87 |
| Simvastatin | Simvastatin | 444 | 83 |
| Metoprolol Succinate | Metoprolol Succinate | 382 | 79 |
| Potassium Chloride | Potassium Chloride | 382 | 70 |
| Famotidine | Famotidine | 369 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 363 | 70 |
| Omeprazole | Omeprazole | 345 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 344 | 72 |
| Trazodone Hcl | Trazodone Hcl | 294 | 54 |
| Fluticasone Propionate | Fluticasone Propionate | 268 | 84 |
| Allopurinol | Allopurinol | 266 | 46 |
| Celecoxib | Celecoxib | 252 | 55 |
| Sertraline Hcl | Sertraline Hcl | 251 | 47 |
| Eliquis | Apixaban | 243 | 37 |
| Alendronate Sodium | Alendronate Sodium | 242 | 45 |
| Buspirone Hcl | Buspirone Hcl | 234 | 45 |
| Meloxicam | Meloxicam | 224 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 220 | 71 |
| Citalopram Hbr | Citalopram Hydrobromide | 220 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 218 | 41 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 195 | 40 |
| Fenofibrate | Fenofibrate | 191 | 35 |
| Ozempic | Semaglutide | 189 | 37 |
| Donepezil Hcl | Donepezil Hcl | 185 | 31 |
| Montelukast Sodium | Montelukast Sodium | 183 | 36 |
| Diclofenac Sodium | Diclofenac Sodium | 177 | 50 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 159 | 27 |
| Carvedilol | Carvedilol | 155 | 30 |
| Fenofibrate | Fenofibrate Nanocrystallized | 154 | 26 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 149 | 32 |
| Ropinirole Hcl | Ropinirole Hcl | 145 | 26 |
| Glimepiride | Glimepiride | 140 | 29 |
| Duloxetine Hcl | Duloxetine Hcl | 137 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 135 | 29 |
| Warfarin Sodium | Warfarin Sodium | 135 | 16 |
| Januvia | Sitagliptin Phosphate | 133 | 19 |
| Finasteride | Finasteride | 115 | 24 |
| Alprazolam | Alprazolam | 109 | 11 |
| Ezetimibe | Ezetimibe | 108 | 23 |
| Paroxetine Hcl | Paroxetine Hcl | 106 | 24 |
| Xarelto | Rivaroxaban | 103 | 17 |
| Metformin Hcl Er | Metformin Hcl | 101 | 23 |
| Farxiga | Dapagliflozin Propanediol | 99 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 98 | 16 |
| Azelastine Hcl | Azelastine Hcl | 96 | 39 |
| Hydralazine Hcl | Hydralazine Hcl | 93 | 25 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 92 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 90 | 11 |
| Tramadol Hcl | Tramadol Hcl | 88 | 21 |
| Trulicity | Dulaglutide | 87 | 14 |
| Lorazepam | Lorazepam | 85 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 85 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 83 | 55 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 80 | 13 |
| Breo Ellipta | Fluticasone/Vilanterol | 80 | 16 |
| Atenolol | Atenolol | 76 | 15 |
| Azithromycin | Azithromycin | 76 | 56 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 76 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 25 |
| Prednisone | Prednisone | 73 | 21 |
| Clonazepam | Clonazepam | 72 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 72 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 72 | 12 |
| Levetiracetam | Levetiracetam | 70 | suppressed |
| Methocarbamol | Methocarbamol | 67 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 65 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 65 | 11 |
| Methylprednisolone | Methylprednisolone | 63 | 52 |
| Spironolactone | Spironolactone | 63 | 14 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 62 | 11 |
| Jardiance | Empagliflozin | 60 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 59 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 27 |
| Synthroid | Levothyroxine Sodium | 58 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 57 | 15 |
| Nifedipine Er | Nifedipine | 57 | 11 |
| Sucralfate | Sucralfate | 57 | 15 |
| Tradjenta | Linagliptin | 56 | suppressed |
| Mounjaro | Tirzepatide | 55 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 52 | 21 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 51 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 49 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 49 | 38 |
| Baclofen | Baclofen | 48 | suppressed |
| Estradiol | Estradiol | 47 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 46 | 34 |
| Bumetanide | Bumetanide | 45 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 45 | 11 |
| Temazepam | Temazepam | 45 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 44 | 18 |
| Methotrexate | Methotrexate Sodium | 43 | suppressed |
| Digoxin | Digoxin | 42 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 42 | suppressed |
| Ramipril | Ramipril | 41 | suppressed |
| Lovastatin | Lovastatin | 40 | suppressed |
| Naproxen | Naproxen | 39 | suppressed |
| Nitroglycerin | Nitroglycerin | 39 | 23 |
| Valsartan | Valsartan | 39 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 38 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 32 |
| Linzess | Linaclotide | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 36 | 15 |
| Diazepam | Diazepam | 36 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 36 | 11 |
| Fenofibrate | Fenofibrate,micronized | 36 | suppressed |
| Glipizide | Glipizide | 36 | suppressed |
| Nystatin | Nystatin | 36 | 19 |
| Mirtazapine | Mirtazapine | 35 | suppressed |
| Vascepa | Icosapent Ethyl | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 34 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Ondansetron Odt | Ondansetron | 34 | 13 |
| Risperidone | Risperidone | 32 | suppressed |
| Glipizide Er | Glipizide | 30 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Primidone | Primidone | 29 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 23 |
| Ciclopirox | Ciclopirox | 27 | 14 |
| Clorazepate Dipotassium | Clorazepate Dipotassium | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 27 | suppressed |
| Cephalexin | Cephalexin | 26 | 15 |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Fosinopril Sodium | Fosinopril Sodium | 25 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 25 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 25 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 24 | suppressed |
| Ranolazine Er | Ranolazine | 24 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 23 | suppressed |
| Entresto | Sacubitril/Valsartan | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 23 | suppressed |
| Multaq | Dronedarone Hcl | 23 | suppressed |
| Zonisamide | Zonisamide | 23 | suppressed |
| Creon | Lipase/Protease/Amylase | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Ketoconazole | Ketoconazole | 22 | suppressed |
| Loperamide | Loperamide Hcl | 22 | suppressed |
| Repatha Sureclick | Evolocumab | 22 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 22 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 22 | suppressed |
| Breyna | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Brilinta | Ticagrelor | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 21 | suppressed |
| Cholestyramine Light | Cholestyramine | 21 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 21 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 21 | suppressed |
| Nexletol | Bempedoic Acid | 21 | suppressed |
| Bupropion Xl | Bupropion Hcl | 20 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 20 | suppressed |
| Leflunomide | Leflunomide | 20 | suppressed |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 19 | suppressed |
| Novolog Flexpen | Insulin Aspart | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 18 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 17 | suppressed |
| Fluconazole | Fluconazole | 17 | 13 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 17 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 17 | 12 |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 11 |
| Sulfasalazine | Sulfasalazine | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 16 |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Phenytoin | Phenytoin | 16 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 16 | suppressed |
| Amoxicillin | Amoxicillin | 15 | 15 |
| Cilostazol | Cilostazol | 15 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 15 | suppressed |
| Gemfibrozil | Gemfibrozil | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Myrbetriq | Mirabegron | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 14 | suppressed |
| Movantik | Naloxegol Oxalate | 14 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Topiramate | Topiramate | 14 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Humulin R | Insulin Regular, Human | 13 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 13 | suppressed |
| Novolin R | Insulin Regular, Human | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Carbamazepine | Carbamazepine | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 12 |
| Clobazam | Clobazam | 12 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 12 | suppressed |
| Fycompa | Perampanel | 12 | suppressed |
| Heather | Norethindrone | 12 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Novolin R Flexpen | Insulin Regular, Human | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Silodosin | Silodosin | 12 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 12 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 12 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 11 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 11 | suppressed |
| Klor-Con M20 | Potassium Chloride | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $110.80 · 6 records | ABBVIE INC. | Auvelity, CAPLYTA, Ozempic, PAXLOVID, REXULTI, Rybelsus, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error